



## (51) International Patent Classification:

*C07D 471/04* (2006.01) *A61P 25/22* (2006.01)  
*A61K 31/437* (2006.01) *A61P 25/24* (2006.01)  
*A61K 31/444* (2006.01) *A61P 25/28* (2006.01)  
*A61P 25/16* (2006.01) *A61P 37/08* (2006.01)  
*A61P 25/18* (2006.01)

## (21) International Application Number:

PCT/IB2014/058840

## (22) International Filing Date:

6 February 2014 (06.02.2014)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

61/766,268 19 February 2013 (19.02.2013) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,  
New York, New York 10017 (US).(72) Inventors: **CHAPPIE, Thomas Allen**; 59 Hemlock Hill  
Road, Carlisle, Massachusetts 01741 (US). **HAYWARD,  
Matthew Merrill**; 3 Pyrus Court, Old Lyme, Connecticut  
06371 (US). **PATEL, Nandini Chaturbhai**; 70 Hope Ave-  
nue, Apt. 205, Waltham, Massachusetts 02453 (US).  
**VERHOEST, Patrick Robert**; 23 Calvin Road, Newton,  
Massachusetts 02460 (US).(74) Agent: **OLSON, A. Dean**; Pfizer Inc., Eastern Point Road  
MS8260-2141, Groton, Connecticut 06340 (US).(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,  
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,  
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,  
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).


## Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a  
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the  
earlier application (Rule 4.17(iii))

## Published:

- with international search report (Art. 21(3))

(54) Title: AZABENZIMIDAZOLE COMPOUNDS AS INHIBITORS OF PDE4 ISOZYMES FOR THE TREATMENT OF CNS  
AND OTHER DISORDERS



(57) Abstract: The present invention is directed to compounds of formula (I); or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined 5 herein. The compounds of formula I are useful as inhibitors of PDE4 for the treatment of CNS and other disorders.